Bispecific Antibody MT-103 Technology Transfer Agreement Signed (Up to $538.9M)
Global technology transfer agreement: Grants Memento Medicines exclusive rights to develop and commercialize bispecific antibody MT-103; total contract amount (company's 50% share) USD 538,875,000 (approx. 781.8 billion KRW; exchange rate 1,450.80 KRW/USD as of 2026.5.10)
Upfront fee of USD 4,000,000 (approx. 5.8 billion KRW) is non-refundable and recognized as guaranteed revenue
Development/regulatory milestones up to USD 41,125,000 and commercialization milestones up to USD 493,750,000 (contingent on achieving specific stages)
Total contract value exceeds 10% of latest fiscal year (2025) revenue (7,101,468 KRW)
Agreement may terminate if clinical trials or regulatory approvals fail; no penalty obligation for the company
KOSDAQ Filing Information
Filing: Material Information on Investment Decision (Execution of Bispecific Antibody MT103 Technology Transfer Agreement)